Tissue Diagnostics Market Size, Share and Analysis by Product (Instruments, Consumables), By Technology (In-situ hybridization, Immunohistochemistry, Digital Pathology, Primary & Special Staining, Others), By Disease (Prostate Cancer, Lung Cancer, Breast Cancer, Skin Cancer, Others), By End User (Hospitals & Clinics, Diagnostics centers, Contract research organization & research laboratories) and Regional Forecast, 2025-2032

The global tissue diagnostics market size was valued at USD 8.85 billion in 2024. The market is projected to grow from USD 10.89 billion in 2025 to USD 46.65 billion by 2032, exhibiting a CAGR of 8.5% during the forecast period.

Tissue diagnostics is widely used in the medical field to analyze a tissue sample for diagnosis of cancer and other disorders. For instance, hematoxylin and eosin stain (H&E), a technology of tissue diagnostics, is often considered as the gold standard by the pathologist for the diagnosis of suspected cancer. Diagnosis and monitoring of various types of cancer are often the most common application of tissue diagnostics, but other types of diseases can also be diagnosed. Tissue diagnostics also leads to the prospect of personalized medicine for various treatment options of cancers.

Tissue diagnostics thus aid in the development of targeted therapies which lead to the prospect of better patient outcomes and also in the prevention of further relapses of the diseases. According to the American Cancer Society (ACS), melanoma or skin of cancer is the most common type of cancer occurring in the U.S., and it is estimated that in 2018, approximately 91,270 new cases of melanomas will occur, comprising of 55,150 in men and 36,120 in women.

To gain extensive insights into the market, Download for Customization

The global tissue diagnostics market is anticipated to grow owing to a number of factors such as the increasing prevalence of various types of cancers, rising demand for preventive care, propelling opportunities in digital pathology, raising awareness campaigns for cancer, advancements in technologies for tissue diagnostics, and efficiency in the diagnosis & monitoring of diseases.

However, factors such as high costs of diagnostic procedures and a dearth of skilled and professional labors associated with tissue diagnostics are responsible for hindering the global tissue diagnostic market growth during the forecast period.

Key Players Covered

Some of the key players present in the global tissue diagnostics market are Abbott, F. Hoffmann-La Roche Ltd, GE Healthcare, Agilent Technologies, Inc., Danaher, Merck Sharp & Dohme Corp., Sakura Finetek Japan Co., Ltd, Thermo Fisher Scientific Inc., BioGenex, Metropolis Healthcare Limited, and others.

SEGMENTATION

Among the segmentation of tissue diagnostics market, cancer in the diseased segment accounts for the highest share in the global market owing to the increasing number of cancer cases, smoking habits, high alcohol consumption rates, and genetic variations. These factors are responsible for propelling the cancer segment in the forecast period as well and contribute to the global growth of the tissue diagnostics market.

Key Insights

• Prevalence of cancer – For key countries, 2018
• Reimbursement scenario – For key countries
• Overview of technological advancements in tissue diagnostics
• Key mergers and acquisitions

Regional Analysis

Geographically, the global tissue diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the tissue diagnostics market owing to factors such as the increasing prevalence of skin & breast cancers, advancing diagnostics & treatment options for cancers, established healthcare system, high healthcare expenditure, increasing investment in tissue diagnostics and rising demand for preventive medical care. Asia Pacific is anticipated to register a higher CAGR owing to increasing incidences & awareness of cancer, development of advanced technologies, large patient population, rising disposable incomes, greater awareness & demand for advanced diagnostic procedures and developing healthcare systems.

Key Industry Developments

• In June 2019, F. Hoffmann-La Roche Ltd, launched VENTANA ROS1 (SP384) Antibody, the first in-vitro diagnostic ROS1 immunohistochemistry assay to detect lung cancer.
• In December 2018, Metropolis Healthcare Limited whose subsidiary Metropolis Histoxpert Digital Services Private Limited, has introduced Metropolis HISTOXPERT DIGITAL DIAGNOSTIC solution for undertaking advanced tissue investigation in India.
• In August 2018, BioGenex launched five new primary antibodies for cancer immunohistochemistry.